Barclays PLC Aclaris Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 20,393 shares of ACRS stock, worth $77,493. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,393

Previous 20,393 -0.0%

Holding current value

$77,493

Previous $23,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$1.12 - $1.4 $22,234 - $27,792	-19,852 Reduced 49.33%	20,393 $23,000
Q2 2024 Aug 14, 2024	SELL	$1.01 - $1.36 $28,301 - $38,108	-28,021 Reduced 41.05%	40,245 $44,000
Q1 2024 May 15, 2024	SELL	$0.92 - $1.44 $99,040 - $155,020	-107,653 Reduced 61.19%	68,266 $85,000
Q4 2023 Feb 15, 2024	SELL	$0.64 - $6.49 $37,267 - $377,919	-58,231 Reduced 24.87%	175,919 $184,000
Q3 2023 Nov 07, 2023	BUY	$6.56 - $10.95 $975,872 - $1.63 Million	148,761 Added 174.22%	234,150 $1.6 Million
Q2 2023 Aug 03, 2023	SELL	$7.89 - $10.64 $26,044 - $35,122	-3,301 Reduced 3.72%	85,389 $885,000
Q1 2023 May 04, 2023	BUY	$7.07 - $17.95 $324,371 - $823,546	45,880 Added 107.17%	88,690 $717,000
Q4 2022 Feb 13, 2023	BUY	$14.33 - $18.37 $374,055 - $479,512	26,103 Added 156.24%	42,810 $674,000
Q3 2022 Nov 03, 2022	SELL	$13.07 - $18.22 $68,774 - $95,873	-5,262 Reduced 23.95%	16,707 $263,000
Q2 2022 Aug 12, 2022	SELL	$10.16 - $17.08 $388,995 - $653,941	-38,287 Reduced 63.54%	21,969 $307,000
Q1 2022 May 16, 2022	SELL	$9.74 - $17.92 $392,151 - $721,495	-40,262 Reduced 40.05%	60,256 $1.04 Million
Q4 2021 Feb 14, 2022	BUY	$12.27 - $18.49 $617,782 - $930,953	50,349 Added 100.36%	100,518 $1.46 Million
Q3 2021 Nov 09, 2021	BUY	$13.38 - $18.8 $513,818 - $721,957	38,402 Added 326.35%	50,169 $903,000
Q2 2021 Aug 13, 2021	BUY	$17.08 - $29.6 $200,672 - $347,770	11,749 Added 65272.22%	11,767 $205,000
Q3 2020 Nov 12, 2020	SELL	$1.5 - $2.71 $12,414 - $22,427	-8,276 Reduced 99.78%	18 $0
Q2 2020 Aug 12, 2020	SELL	$1.04 - $1.73 $2,310 - $3,844	-2,222 Reduced 21.13%	8,294 $13,000
Q1 2020 May 13, 2020	SELL	$0.75 - $2.18 $55,002 - $159,874	-73,337 Reduced 87.46%	10,516 $11,000
Q4 2019 Feb 10, 2020	BUY	$1.02 - $1.97 $68,069 - $131,467	66,735 Added 389.85%	83,853 $159,000
Q3 2019 Nov 14, 2019	SELL	$0.79 - $2.47 $4,658 - $14,565	-5,897 Reduced 25.62%	17,118 $18,000
Q2 2019 Aug 14, 2019	BUY	$2.13 - $7.06 $26,693 - $88,475	12,532 Added 119.55%	23,015 $50,000
Q1 2019 May 15, 2019	BUY	$5.63 - $7.84 $59,019 - $82,186	10,483 New	10,483 $63,000
Q4 2018 Feb 14, 2019	SELL	$6.3 - $15.4 $77,130 - $188,542	-12,243 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$14.38 - $20.89 $147,812 - $214,728	10,279 Added 523.37%	12,243 $178,000
Q2 2018 Aug 14, 2018	SELL	$16.46 - $20.33 $72,654 - $89,736	-4,414 Reduced 69.21%	1,964 $39,000
Q1 2018 May 15, 2018	BUY	$17.08 - $25.64 $31,529 - $47,331	1,846 Added 40.73%	6,378 $111,000
Q4 2017 Feb 14, 2018	SELL	$21.47 - $27.8 $62,799 - $81,315	-2,925 Reduced 39.22%	4,532 $112,000
Q3 2017 Nov 14, 2017	BUY	$23.02 - $28.8 $171,660 - $214,761	7,457	7,457 $192,000

Others Institutions Holding ACRS

# of Institutions

Shares Held

50.7M

Call Options Held

30.6K

Put Options Held

View Full List

About Aclaris Therapeutics, Inc.

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $253M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

More about ACRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account